Last reviewed · How we verify
QIV or TIV
QIV or TIV is a vaccine that stimulates the body's immune system to produce antibodies against influenza.
QIV or TIV is a vaccine that stimulates the body's immune system to produce antibodies against influenza. Used for Prevention of influenza disease caused by influenza A subtype viruses and type B viruses, Prevention of influenza disease in individuals 6 months of age and older.
At a glance
| Generic name | QIV or TIV |
|---|---|
| Sponsor | Seqirus |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
QIV or TIV works by introducing inactivated influenza virus antigens to the body, which triggers an immune response and helps to protect against future infections. This is achieved through the administration of a vaccine that contains inactivated influenza viruses, which are unable to cause disease but can still stimulate an immune response.
Approved indications
- Prevention of influenza disease caused by influenza A subtype viruses and type B viruses
- Prevention of influenza disease in individuals 6 months of age and older
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.
- Immunogenicity Trial of 3 Influenza Vaccines (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5) (PHASE3)
- Flublok or Fluzone With Advax-CpG55.2 or AF03 (PHASE1)
- Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |